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Background: Infection with urinary schistosomiasis and its severity are oncogenic factors for developing carcinoma
of the bladder, whether it is urothelial carcinoma (UC) of a transitional cell type (TCC) or non-urothelial of squamous
cell carcinoma (SCC). In UC it is not defined whether it is schistosomal or not. This led to controversial results in
expression of tumour markers, tumour prognosis, and response to therapy.
Objectives: We assessed the application by immunohistochemistry method (IHC) for detection of schistosomal
antigen in bladder cancer tissue samples to differentiate UC associated with or without schistosomiasis. Urothelial
carcinoma stage, grade, and progression were correlated with the density, intensity, and index of schistosomal
antigen expression. Follow up was done for 2-5 years.
Design and participants: Archival tissue samples of 575 patients were studied: 515 urothelial carcinoma, 30
patients with SCC associated with schistosomiasis, and a control group of 30 patients without schistosomiasis.
Measurements: Expression of schistosomal antigen in tissue was done by IHC using monoclonal antibodies (MAbs)
against schistosomal antigens (SA). Correlation of intensity of antigen expression to clinical and pathological data
was analysed.
Results and limitations: We identified 3 parameters of antigen expression: density, intensity and index with 4
grades for each. SCC-group was 100% positive. UC was positive in 61.4% distributed as follows: Ta: 37.5%, T1: 62%,
and muscle invasive T2-4 were 64%. Upstaging, metastases and recurrence were correlated with high index in T1
and T2-4 tumours.
Conclusion: Urothelial carcinoma associated with schistosomiasis was defined by the positive expression of
schistosomal antigens in tissues detected by lHC using MAbs against schistosomal haematobium. Upstaging and
progression of T1 and T2-4 were correlated with high density, intensity, and index of antigen expression.
Non-schistosomal UC had negative expression for schistosomal antigen, which was detected in 36.5% of cases. These
results would be of significance in differentiating schistosomal from non-schistosomal bladder cancer of UC and would
predict the prognosis in T1, T2-3 tumours. Implementation of IHC using MAbs against SA in UC would help in planning
the proper therapy. Schistosomiasis should be considered as an oncogene for UC in endemic areas.
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Urothelial carcinoma (UC) of the bladder is defined as the
transitional cell carcinoma cell type (TCC). Squamous cell
carcinoma (SCC) is a non-urothelial carcinoma. Scientific
publications investigating bladder carcinoma in endemic
areas with schistosomiasis amalgamated both UC and
SCC as carcinoma associated with schistosomiasis, and
consequently called it schistosomal or bilharzial blad-
der cancer [1,2].
Studies on tumour markers of UC associated with or
without schistosomiasis from endemic areas showed con-
troversial results compared to Western studies [3-6].
Publications dealing with schistosomal bladder lesions
and carcinoma are dating back to 1960 and have been go-
ing on up to now. Their definition of schistosomal bladder
cancer depends upon the clinical history of schistosomia-
sis, former urine analysis positive for schistosoma ova,
history of received antibilharzial therapy, the finding of
schistosoma ova in histopathology of tissue samples, tissue
reaction of cystitis cystica, sandy patches or squamous
metaplasia [4]. These criteria are not accurate and precise,
additionally, the non-detection of schistosoma ova is not
an exclusion possibility of a schistosomal association, as it
is common that the examined tissue samples do not rep-
resent the whole bladder tissue, and the ova deposition is
mostly focal and not diffuse.
The circulating schistosoma antigens would show
the present status of patients but are not an indication
of the past history and of the tissue reaction against
schistosomiasis.
UC would develop in patients living in areas endemic
with schistosomiasis. In spite of not having been infected
with schistosomiasis, they were described as schistosomal
bladder cancer. UC associated with or without schistosom-
iasis had previously not been defined. Its definition would
assist in having a strategic therapeutic plan and would
predict tumour progression.
Schistosomal antibody detection assay in serum is a
sensitive procedure for the detection of circulating schis-
tosomal antigens (CSA) by applying specific schistosoma
haematobium (S.haematobium) monoclonal antibodies
(MAbs) [7-11]. Schistosomal antigens in the bladder
tissue would induce oncogenic cascades leading to
UC [12,13].
Our aim was to establish a definition of UC associated
with schistosomiasis by using the immunohistochemical
technique of applying MAbs prepared against S.haema-
tobium soluble egg antigens (SEA) on tissue samples of
patients with UC and SCC and of control groups.
Materials and methods
Patients
The study included 575 patients. Their archival clinical data
and tissue samples were collected and analysed in multicentric hospital and private clinics, part of the data being
MSc theses. Follow-up of cases ranged from 2 to 5 years.
a) Urothelial Carcinoma
Enrolled in the study were 515 patients. The paraffin
embedded blocks of tissue samples stained with
hematoxylin and eosin were studied by light
microscopy. Examination included’ archival samples
since the first diagnosis. This studied group included
40 patients with Ta, 50 patients with T1, and 425
patients with muscle invasive of T2-4.b) Squamous Cell Carcinoma
Thirty patients with SCC were included representing
the positive reference. Histopathological examination
showed presence of S.haematobium ova with
schistosomal tissue reaction of cystitis cystica, sandy
patches and squamous metaplasia.c) Control Group
Twenty five patients having benign prostatic
hyperplasia (BPH) underwent TURP. The covering
urothelium was processed as control. 5 female
patients diagnosed with interstitial cystitis (IC) had
bladder biopsy. Part of the biopsy was used as
control. Both series were schistosoma negative by
detection of CSA in serum by the use of anti-S.
haematobium Mabs, no history of Bilharziasis and
no Bilharzial tissue reaction.Ethical agreement and Consent
This study was approved by the internal review board of
Theodor Bilharz Research Institute, Cairo- Egypt for
the use of the archival material and data. Written in-
formed consent was obtained from patients for the use
of their data and publish the results of the study, and
any accompanying images.
Monoclonal Antibodies against S.haematobium
(MAbs anti-S.haematobium)
MAbs were prepared according to Cianfrigila [14]. Spleen
cells from eight weeks old female BALB/C mice immunized
with S.haematobium soluble antigens (SEA) were fused
with non-secreting murine myloma cells (P3x63 Ag.8).
Methodology of Galfre [15] was applied, fusion was per-
formed in presence of 43% polyethylene glycol. Hybridomas
were screened for antibodies against S.haematobium SEA
antibodies by ELISA. Hybrids that were highly reactive with
SEA were cloned by the limiting dilution method. Isotype
analysis of MAbs was done using the mouse-hybridoma
subtyping kits. Hybridoma cells were injected intraper-
itoneally into BALB/C mice for ascites production. MAbs
2D/11C and 10B/2C (IgGI) were purified by caprylic acid
treatment followed by ion exchange chromatography.
Table 1 Characterization of studied groups, 575 patients




Control - PBH 25 60-90 (73) 25 0 30
Control - IC 5 40-60 (45) 0 5
Squamous Cell
Carcinoma
30 35-65 (57) 27 3 30
Urothelial Carcinoma Ta 40 15-70 (55) 33 7 515
Urothelial Carcinoma T1 50 40-65 (56) 35 15
Urothelial Carcinoma
T2-4
425 45-74 (60) 381 54
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in samples from 575 patients.
Immunohistochemical Methods (IHM)
Indirect IHC on paraffin sections were applied according
to Maranchie [16]. The paraffin sections were dewaxed,
rehydrated, washed with phosphate buffered saline, incu-
bated with 3% hydrogen peroxide to block endogenous
peroxidase, washed again with phosphate buffer solution.
The sections were boiled for 5 minutes in 10 mmol/l citrate
buffer solution (pH 6.0) for antigen retrieval; sections were
cooled and rinsed in Phosphate buffer solution. MAbs of
anti S.haematobium SEA were incubated for 60 minutes
at room temperature. Secondary antibody was applied
followed by peroxidase-conjugated steptavidin. The dem-
onstration of binding sites with peroxidase reaction was
achieved with 3,3-diaminobenzidine tetrahydrochloride.
The negative control estimation was performed by omitting
the use of pimary antibodies.
Interpretation of S. haematobium Antigen Expression
in Tissues
Using IHC, the presence of S.haematobium antigens in tis-
sues was detected by applying Mabs anti S.haematobium in









Control BPH 25 0 0%
Control IC 5 0 0%
SCC 30 30 100%
Urothelial Carcinoma Ta 40 15 37.5%
Urothelial Carcinoma T1 50 31 62%
Urothelial Carcinoma T2-4 425 270 63.5%
Comments: 1- SCC was 100% positive for density of antigen expression.
2- The number and percentage of degrees of density of antigen expression were ca
3- Total number of positive cases in urothelial carcinoma were 316 out of 515 (61.5a) Negative Control
The negative detection was referred to in the
negative finding of the control groups of BPH and
IC when applying the MAbs on a tissue section and
on another section omitting its application
respectively. Both techniques showed no expression
of schistosoma antigen. This conclusion is described
as negative or 0%.










%).Thirty patients who had SCC and presence of
schistosoma ova in their tissue samples, chronic
schistosomal lesions of cystitis cystica, sandy patches
as well as squamous metaplasia were the positive
control. They showed positive expression of tissue
against S.haematobium antigens with high density
and strong intensity and were considered to be the
highest level of positivity of 100%.c) Density of Schistosomal Antigen Expression
Percentage of positively stained cells in one
microscopic field is referred to as density. A number
of positively stained cells were recorded in five
consecutive fields with the highest expression. The
percentage was calculated from the mean. Degrees
of density of schistosomal antigen expression were
recorded as: negative (0%); one + (1% – 25%);
two ++ (26% - 50%); three+++ (51% - 100%).
Another nomenclature was: negative, low, moderate,
high density.d) Intensity of Schistosomal Antigen Expression
Intensity describes the deepness of colour intensity
in the stained cells. The intensity of staining
represents the body reaction towards schistosomal
antigen. It is evaluated relative to the normal
urothelial cell expression in normal control. Positive
expression of S. haematobium antigen appears as a
brown colour. Degrees in intensity of schistosomaldied groups (580 patients)
Density of schistosomal antigen expression in tissue
detected Low Moderate High
% 0 1%-25% 26%-50% 51%-100%
(100%) 0 0 0
(100%) 0 0 0
(0%) 0 8 (26.7%) 22 (73.3%)
(62.5%) 12 (80%) 3 (20.0%) 0 (0%)
(38.0%) 14 (45.2%) 9 (29.0%) 8 (25.8%)
(36.5%) 57 (21.1%) 120 (44.4%) 93 (34.5%)
d in positive cases only.
Figure 1 Positive schistosomal antigen expression in squamous cell carcinoma group a. Shows well differentiated SCC with schistosoma
ova deposition. Hematoxylin and eosin stain , with omitting the monoclonal antibodies against S. haematobium did not show the antigen
reaction. Original magnification × 200. b. Shows SCC with schistosoma ova deposition. Schistosomal antigen expression was positive with high
intensity, density and index. Original magnification × 200. c. Shows SCC with high positive expression of Schistosomal antigen on application of
Mab anti-S.Haematobium. Original magnification × 200.
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light intensity: one + (1% – 25%); moderate intensity:
two ++ (26% - 50%); strong intensity: three+++
(51% - 100%). Another nomenclature was: negative,
light, moderate, strong intensity.e) Index of Schistosomal Antigen Expression
Index is referred to the sum of density and intensity
of schistosomal antigen expression for each case. It
is the mean of density and intensity of the positive
antigen expression. The index was calculated for
each case independently. Four ranges of indices were
identified. 0: negative; low index: 1% - 25%; medium
index: 25% - 50%; high index: 51% - 100%.Results
Characteristics of the studied groups
The study included 575 patients. 30 cases were negative
control as described in (Table 1). High positive refer-
ence was in 30 cases of SCC due to schistosomiasis that
was proved by light microscopy and IHC methods, in
addition to clinical history thse cases were the positive
control. Urothelial carcinoma patients were 515, who
had had different stages of UC of Ta, T1 and T2-4. Age
and sex distribution of the 575 cases are elaborated in
Table 1.Figure 2 Shows T1 urothelial carcinoma with positive
schistosomal antigen expression with moderate intensity
and density. Original magnification × 200.Density of schistosomal antigen expression in urothelial
carcinoma
The distribution of density in all studied groups was
summarised in (Table 2).Negative control groups
Twenty five men with BPH and five women with IC
showed negative for expression of schistosomal antigen
in urinary bladder tissue samples, and were negative for
density expression.
Positive control group
Thirty patients with SCC were highly positive for schis-
tosomal antigen expression, all cases were 100% over
Figure 3 Shows muscle invasive urothelial carcinoma without shistosoma ova deposition or schistosomal tissue reaction. Schistosomal
antigen expression was positive with high intensity, density, and index. Original magnification × 200.
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in 26.7%., there were neither negative nor low density
cases (Figure 1a,b,c).
Urothelial carcinoma group
Evaluated were 515 cases of UC. Ta tumours were 40 pa-
tients of whom 25 showed negative expression (62.5%).
15 were positive (37.5%). Low density was in 80%; mod-
erate density in 20%.
T1 tumours were 50 cases. Negative expression was in









Control BPH 25 0 0%
Control IC 5 0 0%
SCC 30 30 100%
Urothelial Carcinoma Ta 40 15 37.5%
Urothelial Carcinoma T1 50 31 62%
Urothelial Carcinoma T2-4 425 270 63.5%
Comments: 1- SCC was 100% positive for intensity of antigen expression.
2- The number and percentage of degrees of intensity of antigen expression were
3- Total number of positive cases in urothelial carcinoma were 316 out of 515 (61.5of density was high in 25.8%, medium in 29%, and low in
45.2% (Figure 2).
T2-4 was evaluated in 425 cases of which 155 were
negative (36.5%) (Figure 3). In the 270 positive cases
(63.5%), the density was high: 34.5%, moderate: 44.5%,
and low: 21%.
Intensity of schistosomal antigen expression
The intensity represented the magnitude of tissue reac-
tion to the schistosomal antigen. Intensity of antigen ex-
pression in all studied groups was elaborated in (Table 3).ent studied groups (580 patients)
Intensity of schIstosomal antigen expression in tissue
No antigen Light Moderate Strong
0% 0 1%-25% 26%-50% 51%-100%
25 (100%) 0 0 0
5 (100%) 0 0 0
0 (0%) 0 4 (13.3%) 26 (86.7%)
25 (62.5%) 10 (66.7%) 5 (33.3%) 0 (0%)
19 (38.0%) 5 (16.2%) 16 (51.6%) 10 (32.2%)
155 (36.5%) 64 (23.7%) 130 (48.1%) 76 (28.2%)
calculated in positive cases only.
%).









Index of schIstosomal antigen expression in tissue
Index 0 Low index Medium index High index
0% 0 1%-25% 26%-50% 51%-100%
Control BPH 25 0 0% 25 (100%) 0 0 0
Control IC 5 0 0% 5 (100%) 0 0 0
SCC 30 30 100% 0 (0%) 0 4 (13.3%) 26 (86.7%)
Urothelial Carcinoma Ta 40 15 37.5% 25 (62.5%) 13 (86.7%) 2 (13.3%) 0 (0%)
Urothelial Carcinoma T1 50 31 62% 19 (38.0%) 6 (19.4%) 16 (51.6%) 9 (29%)
Urothelial Carcinoma T2-4 425 270 63.5% 155 (36.5%) 33 (12.2%) 110 (40.8%) 127 (47%)
*Index = (Density + Intensity)/2.
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tive group of SCC showed strong expression in 86.7%,
while 13.3% had moderate intensity. Light intensity was
not recorded.
Ta tumors showed positive intensity in 37.5%, light in-
tensity in 66.7% and moderate intensity in 33.3%.
T1 tumors showed strong intensity in 32.2%, moderate
in 51.6%, and light intensity in 16.2% of cases.
T2-4 tumors were positive in 270/425 (63.5%) cases,
negative cases were 36.5%. 24.7% of positive cases had
light intensity, 48% moderate, and 28% strong intensity.Index of schistosomal antigen expression
Index of expression of antigen expression in all studied
groups was elaborated in (Table 4).
Significance of index of expression of schistosomal anti-
gen and tumor progression was elaborated in (Table 5).
Index was recorded for every patient and correlated with
the tumour progression in T1 and recurrence in T2-4.
Ta positive cases had low index in 86.7%, medium index
in 13.3%, high index was not found. In 5 years follow-up,
no case had progression.
T1 positive cases were 19.4% with low index, with no
upstaging. 16/31 cases of T1 tumour had a medium index
of 51.5% with 81% having upstaging to muscle invasion in
five years follow-up. T1 with high index were 29%, all of
them had upstaging.
T2-4 were 270 out of 425 with 63.5% positive index:
12.2% low index, 40.8% medium and 47% high index.Table 5 Correlation between index of schistosomal antigen e






No. of cases Progressio
Urothelial Carcinoma Ta 15 12 (80%) 0 (0%)
Urothelial Carcinoma T1 31 6 (19.4%) 0 (0%)
Urothelial Carcinoma T2-4 270 36 (13.3%) 7/36 (19.4%
Comments: 1-Progression is estimated for each degree of the index.
2-Tumour progression indicates upstaging in T1 tumors.
3-Tumour progression indicates local recurrence and metastases in T2-4 after definiProgression was found in 21.2% of the low, 81.8% of the
medium and 95% of the high index group.
The SCC tumours had a high index in 68.7% and a
medium index in 13.3%.
Discussion
The urothelial carcinoma associated with schistosomiasis
has not been defined or standardised in literature [1-3].
For the definition of schistosomal UC, we introduced
the use of an immunohistochemical method to evaluate
the expression of schistosomal antigens in tissue using
MAbs anti-S.haematobium in 575 patients. 30 were SCC
and served as positive control, 30 with BPH and IC as
negative control. 515 were UC of Ta, T1, T2-4.
Our results showed that 61.4% of the 515 urothelial
carcinoma cases were positive while 38.6% were nega-
tive. This finding differentiated between the schistosomal
and non-schistosomal urothelial carcinoma.
The density of schistosomal antigen expression de-
notes the antigen load in tissue that was found high in
T1, T2-4, contrary to low density in Ta tumours.
Intensity of schistosomal antigen expression repre-
sented the severity of tissue and cellular reaction against
schistosomal antigen. It was found to be strong and
moderate in T1, T2-4, while low in Ta tumours.
Our study indicated that high density and strong in-
tensity were associated with invasive stages where Ta
had a low density and light intensity.
The impact of schistosomiasis on the urinary bladder had
been considered to be a promoter for carcinoma [12,13]xpression in urothelial carcinoma positive cases and
Medium index High index
n No. of cases Progression No. of cases Progression
3 (20%) 0 (0%) 0 (0%) 0 (0%)
16 (51.6) 13/16 (81.2%) 9 (29%) 9/9 (100%)
) 119 (44.1%) 90/119 (75.6%) 115 (42.6%) 109/127 (85.8%)
tive therapy.
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ence of strong intensity and high density in high stages
of tumours denoted the schistosomal antigen tumour
genesis in urothelial carcinoma associated with schis-
tosomiasis [12].
Our study indicated that index of schistosomal antigen
was a predictive marker for progression in schistosomal
urothelial carcinoma, for upstaging, recurrence, and/or
metastases. Our results indicate that for the achievement
of proper therapy and prediction of prognosis of UC as-
sociated with schistosomiasis, detection of schistosomal
antigen parameters is crucial. The study showed that the
strong and high antigen expression defined by index of
antigen expression has an impact on tumour upstaging
and progression, where high index indicated tumour up-
staging, progression, and aggressiveness.
Conclusion
Urothelial carcinoma associated with schistosomiasis is
defined by the positive expression of schistosomal anti-
gens in tissues that were detected by IHC using MABs
against S. haematobium. In our study, we described three
parameters of tissue expression: Density and intensity with
4 grades, and index with 3 grades of low, medium, and
high. They denoted the tissue reaction to Schistosomal an-
tigens and its tumourogenesis. High schistosomal antigen
expression was statistically significant with higher tumour
stage, high index was significant for upstaging in T1 and
for progression to recurrence and metastases in T2-3 tu-
mors. Low antigen expression with low density, intensity
and zero index were correlated with low risk tumors of
Ta. Negative expression of antigens was found in 36.5% of
patients with UC who should be excluded from the
group of schistosomal bladder cancer. High index of schis-
tosomal antigens demands a close surveillance and early
radical intervention.
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